Literature DB >> 31727592

Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.

Daniel J Wolter1, Frankline M Onchiri2, Julia Emerson1, Mimi R Precit3, Michael Lee3, Sharon McNamara2, Laura Nay2, Marcella Blackledge2, Ahmet Uluer4, David M Orenstein5, Michelle Mann6, Wynton Hoover7, Ronald L Gibson2, Jane L Burns1, Lucas R Hoffman8.   

Abstract

BACKGROUND: Staphylococcus aureus is the bacterium cultured most often from respiratory secretions of people with cystic fibrosis. Both meticillin-susceptible S aureus and meticillin-resistant S aureus (MRSA) can adapt to form slow-growing, antibiotic-resistant isolates known as small-colony variants that are not routinely identified by clinical laboratories. We aimed to determine the prevalence and clinical significance of S aureus small-colony variants and their subtypes among children with cystic fibrosis.
METHODS: The Small Colony Variant Staphylococcus aureus (SCVSA) study was a 2-year longitudinal study of children aged 6-16 years at five US cystic fibrosis centres, using culture methods sensitive for small-colony variants. Children were eligible if they had a documented diagnosis of cystic fibrosis and a minimum of two cystic fibrosis clinic visits and two respiratory cultures in the previous 12 months at enrolment. Participants attended clinic visits quarterly, at which respiratory tract samples were taken and measures of lung function (percentage of predicted forced expiratory volume in 1 s [FEV1] and frequency of respiratory exacerbations) were recorded. We determined the prevalence of small-colony variants and their subtypes, and assessed their independent associations with lung function and respiratory exacerbations using linear mixed-effects and generalised estimating equation logistic regression models. Analyses included both univariate models (unadjusted) and multivariate models that adjusted for potential confounders, including age, sex, race, baseline microbiology, treatment with CFTR modulator, and CTFR genotype.
FINDINGS: Between July 1, 2014, and May 26, 2015, we enrolled 230 children. Participants were followed-up for 2 years, with a mean of 6·4 visits (SD 1·14) per participant (range 2-9 visits) and a mean interval between visits of 3·94 months (SD 1·77). Across the 2-year period, S aureus small-colony variants were detected in 64 (28%) participants. Most (103 [56%] of 185) of the small-colony variants detected in these participants were thymidine dependent. Children with small-colony variants had significantly lower mean percentage of predicted FEV1 at baseline than did children without small-colony variants (85·5 [SD 19] vs 92·4 [SD 18·6]; p=0·0145). Small-colony variants were associated with significantly lower percentage of predicted FEV1 throughout the study in regression models, both in univariate analyses (regression coefficient -7·07, 95% CI -12·20 to -1·95; p=0·0068) and in multivariate analyses adjusting for potential confounders (-5·50, -10·51 to -0·48; p=0·0316). Small colony variants of the thymidine-dependent subtype had the strongest association with lung function in multivariate regression models (regression coefficient -10·49, -17·25 to -3·73; p=0·0024). Compared with children without small-colony variants, those with small-colony variants had significantly increased odds of respiratory exacerbations in univariate analyses (odds ratio 1·73, 95% CI 1·19 to 2·52; p=0·0045). Children with thymidine-dependent small-colony variants had significantly increased odds of respiratory exacerbations (2·81, 1·69-4·67; p=0·0001), even after adjusting for age, sex, race, genotype, CFTR modulator, P aeruginosa culture status, and baseline percentage of predicted FEV1 (2·17, 1·33-3·57; p=0·0021), whereas those with non-thymidine-dependent small-colony variants did not. In multivariate models including small-colony variants and MRSA status, P aeruginosa was not independently associated with lung function (regression coefficient -4·77, 95% CI -10·36 to 0·83; p=0·10) and was associated with reduced odds of exacerbations (0·54, 0·36 to 0·81; p=0·0028). Only the small-colony variant form of MRSA was associated with reduced lung function (-8·44, -16·15 to -0·72; p=0·0318) and increased odds of exacerbations (2·15, 1·24 to 3·71; p=0·0061).
INTERPRETATION: Infection with small-colony variants, and particularly thymidine-dependent small-colony variants, was common in a multicentre paediatric population with cystic fibrosis and associated with reduced lung function and increased risk of respiratory exacerbations. The adoption of small-colony variant identification and subtyping methods by clinical laboratories, and the inclusion of small-colony variant prevalence data in cystic fibrosis registries, should be considered for ongoing surveillance and study. FUNDING: The Cystic Fibrosis Foundation and the National Institutes of Health.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31727592      PMCID: PMC6924508          DOI: 10.1016/S2213-2600(19)30365-0

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  38 in total

1.  Prevalence and genetic diversity of Staphylococcus aureus small-colony variants in cystic fibrosis patients.

Authors:  S Yagci; G Hascelik; D Dogru; U Ozcelik; B Sener
Journal:  Clin Microbiol Infect       Date:  2012-01-27       Impact factor: 8.067

Review 2.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  Thymidine-requiring Staphylococcus aureus.

Authors:  P D Sparham; D I Lobban; D C Speller
Journal:  Lancet       Date:  1978-01-14       Impact factor: 79.321

Review 4.  Review: Staphylococcus aureus and MRSA in cystic fibrosis.

Authors:  Christopher H Goss; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2011-06-29       Impact factor: 5.482

5.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

6.  Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.

Authors:  Michael S Schechter; Warren E Regelmann; Gregory S Sawicki; Lawrence Rasouliyan; Donald R VanDevanter; Margaret Rosenfeld; David Pasta; Wayne Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2014-12-19

7.  Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.

Authors:  Jeffery T Zobell; Kevin L Epps; David C Young; Madison Montague; Jared Olson; Krow Ampofo; Melissa J Chin; Bruce C Marshall; Elliott Dasenbrook
Journal:  Pediatr Pulmonol       Date:  2015-01-05

8.  Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.

Authors:  Silke Besier; Christina Smaczny; Christian von Mallinckrodt; Andreas Krahl; Hanns Ackermann; Volker Brade; Thomas A Wichelhaus
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

9.  Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis.

Authors:  P H Gilligan; P A Gage; D F Welch; M J Muszynski; K R Wait
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

10.  In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus.

Authors:  Indranil Chatterjee; Andre Kriegeskorte; Andreas Fischer; Susanne Deiwick; Nadine Theimann; Richard A Proctor; Georg Peters; Mathias Herrmann; Barbara C Kahl
Journal:  J Bacteriol       Date:  2007-09-28       Impact factor: 3.490

View more
  11 in total

1.  Repeated isolation of an antibiotic-dependent and temperature-sensitive mutant of Pseudomonas aeruginosa from a cystic fibrosis patient.

Authors:  Daniel J Wolter; Alison Scott; Catherine R Armbruster; Dale Whittington; John S Edgar; Xuan Qin; Anne Marie Buccat; Sharon McNamara; Marcella Blackledge; Adam Waalkes; Stephen J Salipante; Robert K Ernst; Lucas R Hoffman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

2.  Thymidine starvation promotes c-di-AMP-dependent inflammation during pathogenic bacterial infection.

Authors:  Qing Tang; Mimi R Precit; Maureen K Thomason; Sophie F Blanc; Fariha Ahmed-Qadri; Adelle P McFarland; Daniel J Wolter; Lucas R Hoffman; Joshua J Woodward
Journal:  Cell Host Microbe       Date:  2022-04-18       Impact factor: 31.316

3.  Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic Fibrosis Staphylococcus aureus Airway Infection.

Authors:  Dustin R Long; Daniel J Wolter; Michael Lee; Mimi Precit; Kathryn McLean; Elizabeth Holmes; Kelsi Penewit; Adam Waalkes; Lucas R Hoffman; Stephen J Salipante
Journal:  Am J Respir Crit Care Med       Date:  2021-05-01       Impact factor: 21.405

4.  Genotypic and Phenotypic Diversity of Staphylococcus aureus Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with Pseudomonas aeruginosa.

Authors:  Eryn E Bernardy; Robert A Petit; Vishnu Raghuram; Ashley M Alexander; Timothy D Read; Joanna B Goldberg
Journal:  mBio       Date:  2020-06-23       Impact factor: 7.867

5.  Genetic Association With Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin.

Authors:  Nasenien Nourkami-Tutdibi; Klemens Freitag; Michael Zemlin; Erol Tutdibi
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

6.  Characteristics of Staphylococcus aureus small colony variants isolated from wound specimen of a tertiary care hospital in China.

Authors:  Changhang Min; Haichen Wang; Fengjun Xia; Mengli Tang; Jun Li; Yongmei Hu; Qingya Dou; Mingxiang Zou
Journal:  J Clin Lab Anal       Date:  2021-11-27       Impact factor: 2.352

Review 7.  CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.

Authors:  Francesca Saluzzo; Luca Riberi; Barbara Messore; Nicola Ivan Loré; Irene Esposito; Elisabetta Bignamini; Virginia De Rose
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

8.  Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis.

Authors:  Deirdre Gilpin; Lucas R Hoffman; Agathe Ceppe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2021-06-06       Impact factor: 5.482

Review 9.  Consequences of Metabolic Interactions during Staphylococcus aureus Infection.

Authors:  Alice Prince; Tania Wong Fok Lung
Journal:  Toxins (Basel)       Date:  2020-09-09       Impact factor: 4.546

10.  Association of Diverse Staphylococcus aureus Populations with Pseudomonas aeruginosa Coinfection and Inflammation in Cystic Fibrosis Airway Infection.

Authors:  Marie K Wieneke; Felix Dach; Claudia Neumann; Dennis Görlich; Lena Kaese; Theo Thißen; Angelika Dübbers; Christina Kessler; Jörg Große-Onnebrink; Peter Küster; Holger Schültingkemper; Bianca Schwartbeck; Johannes Roth; Jerzy-Roch Nofer; Janina Treffon; Julia Posdorfer; Josefine Marie Boecken; Mariele Strake; Miriam Abdo; Sophia Westhues; Barbara C Kahl
Journal:  mSphere       Date:  2021-06-23       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.